CD8A and hepatocellular carcinoma: Our results revealed a very interesting counteraction; an increased expression of MHC II on both HCC and non-HCC hepatocytes and activation of PBMCs followed by an enhanced viability of MHC-II-expressing HCC cells with a concomitant apoptosis of the activated CD8+ T cells.